Four cases of ticlopidine-induced cholestatic hepatitis / 대한내과학회지
Korean Journal of Medicine
; : 557-561, 2002.
Article
Dans Ko
| WPRIM
| ID: wpr-169315
Responsable en Bibliothèque :
WPRO
ABSTRACT
Ticlopidine, a potent antiplatelet agent, is widely used for treatment of coronary artery disease and cerebrovascular disease. Adverse effects has been reported in 10% to 20% of patients receiving ticlopidine. The most commom adverse effects were gastrointestinal disturbance, skin rash, but cholestatic hepatitis with jaundice was rare (0.1% incidence). We have recently experienced four cases of ticlopidine-induced cholestatic hepatitis after coronary artery stent insertion. Jaundice developed within 1 month of starting ticlopidine at recommended daily doses. In all cases, jaundice resolved and serum liver enzymes improved over a period of months after drug withdrawal. Therefore, clinicians should be aware of the reversible condition of ticlopidine-induced cholestatic jaundice that slowly resolves after drug withdrawal.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Maladie des artères coronaires
/
Ticlopidine
/
Endoprothèses
/
Vaisseaux coronaires
/
Ictère rétentionnel
/
Exanthème
/
Hépatite
/
Ictère
/
Foie
Limites du sujet:
Humans
langue:
Ko
Texte intégral:
Korean Journal of Medicine
Année:
2002
Type:
Article